Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Scopus)
46 Downloads (Pure)

Abstract

Context: Peptide receptor radionuclide therapy (PRRT) with [Lutetium-177-DOTA-Tyr3]octreotate (177Lu-DOTATATE) results in an increase of progression-free survival and quality of life in patients with progressive, well-differentiated neuroendocrine neoplasms (NENs). Objective: To study the effect of 177Lu-DOTATATE in patients with carcinoid syndrome and radiologically stable or newly diagnosed disease treated solely for the purpose of symptom reduction. Design: Retrospective cohort study. Setting: Tertiary care hospital. Patients: Twenty-two patients with a metastatic midgut NEN, elevated urinary 5-hydroxyindolacetic acid excretion, and flushing and/or diarrhea despite treatment with a somatostatin analog, without documented disease progression. Intervention: PRRT with 177Lu-DOTATATE (intended cumulative dose: 29.6 GBq) with a primary aim to reduce symptoms. Results: After PRRT, mean bowel movement frequency (BMF) decreased from 6.1 ± 3.4 to 4.6 ± 3.6 per day (P = 0.009). Flushes decreased from 4.3 ± 2.9 to 2.4 ± 2.7 flushes per day (P = 0.002). A decrease of BMF of more than 30% occurred in 47% of patients with baseline BMF of 4 or more (n = 17). In patients with ≥2 episodes of flushing a day (n = 15), 67% of patients had more than 50% decrease of daily flushing. A decrease in urinary 5-hydroxyindolacetic acid excretion of more than 30% was seen in 56% of patients. The European Organization for Research and Treatment of Cancer-Core Module diarrhea subscale score showed a trend toward improvement by an average of 16.7 ± 33.3 points (P = 0.11). Conclusion: PRRT with 177Lu-DOTATATE effectively reduced diarrhea and flushing in patients with carcinoid syndrome and can be considered for symptomatic treatment of carcinoid syndrome insufficiently controlled with somatostatin analogs.

Original languageEnglish
Pages (from-to)E3665-E3672
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume106
Issue number9
Early online date4 May 2021
DOIs
Publication statusPublished - 1 Sept 2021

Bibliographical note

Publisher Copyright:
© 2021 The Author(s). Published by Oxford University Press on behalf of the Endocrine Society.

Fingerprint

Dive into the research topics of 'Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome'. Together they form a unique fingerprint.

Cite this